Black Diamond Therapeutics, Inc.
BDTXNASDAQHealthcare● Active
$1.90
$-0.07(-3.55%)
Market Cap$108873371
P/E Ratio—
52W High$4.94
52W Low$1.9
Black Diamond Therapeutics, Inc. (BDTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BDTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $70.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.33M | $0.00M | $0.44M | $0.00M | $0.00M |
| Gross Profit | $69.67M | $0.00M | ($0.44M) | $0.00M | $0.00M |
| Gross Margin %(computed) | 99.54% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $33.56M | $51.31M | $58.91M | $64.44M | $96.83M |
| G&A Expenses | $16.57M | $27.47M | $27.11M | $28.39M | $30.04M |
| Total Operating Expenses | $49.80M | $78.78M | $86.02M | $92.83M | $126.87M |
| Operating Income | $19.87M | ($78.78M) | ($86.46M) | ($92.83M) | ($126.87M) |
| Operating Margin %(computed) | 28.39% | — | — | — | — |
| Interest Income | $4.06M | $2.18M | $1.92M | $2.03M | $3.46M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | $22.37M | ($69.68M) | ($82.44M) | ($91.17M) | ($125.60M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | $22.37M | ($69.68M) | ($82.44M) | ($91.17M) | ($125.60M) |
| Net Margin %(computed) | 31.95% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 |
| Wtd Avg Shares | 56.87M | 55.03M | 43.95M | 36.23M | 36.19M |
| EBITDA | $20.20M | ($78.44M) | ($86.02M) | ($92.32M) | ($126.67M) |
| EBITDA Margin %(computed) | 28.85% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Black Diamond Therapeutics, Inc. data
About Black Diamond Therapeutics, Inc. (BDTX) Income Statement
Black Diamond Therapeutics, Inc. (BDTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BDTX reported revenue of $0.07B, gross profit of $0.07B (gross margin 99.54%), and net income of $0.02B — a net profit margin of 31.95%.
Frequently asked questions
BDTX · 4 questionsBlack Diamond Therapeutics, Inc. (BDTX) reported revenue of $0.07B for 2025, up —% year-over-year.
BDTX revenueBDTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08